Literature DB >> 28731189

Identification of pivotal genes and pathways for spinal cord injury via bioinformatics analysis.

Zonghao Zhu1, Qiang Shen2, Liang Zhu2, Xiaokang Wei2.   

Abstract

The present study aimed to identify key genes and pathways associated with spinal cord injury (SCI) and subsequently investigate possible therapeutic targets for the condition. The array data of GSE20907 was downloaded from the Gene Expression Omnibus database and 24 gene chips, including 3‑day, 4‑day, 1‑week, 2‑week and 1‑month post‑SCI together with control propriospinal neurons, were used for the analysis. The raw data was normalized and then the differentially expressed genes (DEGs) in the (A) 2‑week post‑SCI group vs. control group, (B) 1‑month post‑SCI group vs. control group, (C) 1‑month and 2‑week post‑SCI group vs. control group, and (D) all post‑SCI groups vs. all control groups, were analyzed with a limma package. Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses for DEGs were performed. Cluster analysis was performed using ClusterOne plugins. All the DEGs identified were associated with immune and inflammatory responses. Signal transducer and activator of transcription 3 (STAT3), erb‑B2 receptor tyrosine kinase 4 (ERBB4) and cytochrome B‑245, α polypeptide (CYBA) were in the network diagrams of (A), (C) and (D), respectively. The enrichment analysis of DEGs identified in all samples demonstrated that the DEGs were also enriched in the chemokine signaling pathway (enriched in STAT3) and the high‑affinity immunoglobulin E receptor (FcεRI) signaling pathway [enriched in proto‑oncogene, src family tyrosine kinase (LYN)]. Immune and inflammatory responses serve significant roles in SCI. STAT3, ERBB4 and CYBA may be key genes associated with SCI at certain stages. Furthermore, STAT3 and LYN may be involved in the development of SCI via the chemokine and FcεRI signaling pathways, respectively.

Entities:  

Mesh:

Year:  2017        PMID: 28731189      PMCID: PMC5646972          DOI: 10.3892/mmr.2017.7060

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


Introduction

Spinal cord injury (SCI) is caused by incident trauma or stroke, infection, inflammation and several congenital disorders (1,2). In the UK, ~40,000 people suffer from SCI with an annual incidence of 13 per million (3). There are ~60,000 new cases of SCI reported in China and 12,000 new cases in the USA every year (4,5). SCI may cause significant mortality and morbidity (6). There is no effective therapy for SCI and it is prevalent in a number of different countries (7,8). Therefore, it is necessary to identify an effective treatment for SCI, and identify specific genes or pathways that are associated with SCI and may be able to provide novel ways of treating this condition. A number of achievements associated with molecular mechanism of SCI have been made in previous years. The pathobiology of SCI comprises a primary mechanical insult to the spinal cord and a delayed secondary injury; the secondary injury may instigate apoptotic and necrotic cell death mechanisms (2). Neuroinflammation is a significant component for secondary injury in SCI (9) and the expression of apoptotic genes is increased, whereas the expression of anti-apoptotic genes is reduced (10). Axonal regeneration and functional recovery following SCI may be promoted by the inhibition of ephrin type-A receptor 4 in wild-type mice (11). A temporary block of the interleukin-6 signaling pathway modifies the inflammatory response following SCI and thus promotes the regeneration of the spinal cord (12). Jin et al (13) suggested that the oxidative phosphorylation and central nervous system disease signaling pathways, in addition to the cell cycle and immune system pathways, served significant roles in the progression of SCI. Lai et al (14) indicated that immune response, olfactory transduction and cell cycle pathways were associated with SCI. However, certain key genes and pathways of SCI at different stages have not been completely studied. Further investigation is necessary to elucidate these key genes and pathways to provide possible therapeutic targets for the treatment of SCI. Previous studies with the microarray data of GSE20907 have indicated that oligodendrocyte transcription factor 1, activating transcription factor 3, jun proto-oncogene, vascular endothelial growth factor A, cell division cycle 20, CD74 molecule, major histocompatibility complex, class II invariant chain, bromodomain containing 2 and SMAD family member 1 are key genes associated with SCI, and that SCI is associated with cardiovascular disease and cancers (13–15). The present study identified the differentially expressed genes (DEGs) at different stages of SCI based on the microarray data of GSE20907. Subsequently, functional enrichment analyses for DEGs were performed. A protein-protein interaction (PPI) network was constructed. The present study aimed to identify certain other key genes and pathways in SCI at different stages and investigate potential therapeutic targets of the disease.

Materials and methods

Microarray data

The array data of GSE20907 was downloaded from the Gene Expression Omnibus database, which is based on the platform of GPL6247 (Affymetrix Rat Gene 1.0 ST Array; Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and was deposited by Siebert et al (16). A total of 24 gene chips, comprising 3-day, 4-day, 1-week, 2-week and 1-month post-SCI together with control propriospinal neurons, were used for the analysis. The sample numbers of every time point are presented in Table I.
Table I.

Sample numbers of every time point.

Time pointControlPost-SCI
3 days04
4 days40
1 week40
2 weeks42
1 month42

SCI, spinal cord injury.

Data preprocessing

The raw expression data were normalized using the robust multiarray average algorithm in oligo (17). Following the removal of the internal standard probe, the boxplot was performed for the expression values of every chip prior to and following normalization.

DEGs analysis

The DEGs in (A) 2-week post-SCI group vs. control group, (B) 1-month post-SCI group vs. control group, (C) 1-month and 2-week post-SCI group vs. control group, and (D) all post-SCI group vs. all control group, were analyzed with a limma package (18); |log2FC (fold-change)|≥0.5 and false discovery rate ≤0.01 were set as the threshold criteria. Venn diagrams were plotted for these four comparison groups by a Venn diagrams package (19), and the overlaps of DEGs were obtained. The heatmaps were obtained for the expression values of DEGs by Pheatmap function (20) and if the identified DEGs could be distinguished the corresponding group was verified.

Gene Ontology (GO) and pathway enrichment analyses

The database for annotation, visualization and integrated discovery (DAVID) is an integrated data-mining environment and is used for the analysis of gene lists (21). GO (geneontology.org) is a tool used to annotate genes by collecting a defined, structured and controlled vocabulary (22). The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database used to put associated gene sets into their respective pathways (23). The DEGs in four comparison groups were submitted to DAVID. Subsequently, GO annotation and KEGG pathway enrichment analyses were performed. Gene counts ≥5 and a P≤0.01 were set as the threshold values.

PPI network analysis

The DEGs were imported into the BisoGenet plugin in Cytoscape (24), known interactions were searched with the Biomolecular Interaction Network Database (BIND) (25) and the network diagrams were plotted. At the same time, cluster analysis was performed using default parameter of the ClusterOne plugin in Cytoscape (26) with P<0.01.

Results

Data preprocessing and DEG screening

The boxplots of samples prior to and following normalization are presented in Fig. 1. Volcano plots for the groups are presented in Fig. 2. The results demonstrated that the expression values of each sample were close to the same following normalization.
Figure 1.

Boxplots of sample data (A) prior to and (B) following normalization. The lateral axis represents names of samples and the longitudinal axis represents expression levels. The horizontal line in the middle of post represents the expression levels of each sample. If the line of each sample was close to the same following normalization, then that indicated that all data were successfully normalized. Ctrl, control; post, post spinal cord injury.

Figure 2.

Volcano plot of (A) 2-week post-SCI group vs. control group, (B) 1-month post-SCI group vs. control group, (C) 1-month and 2-week post-SCI group vs. control group, and (D) all post-SCI groups vs. all control groups. SCI, spinal cord injury, FC, fold-change.

A total of 148 DEGs (31 downregulated and 117 upregulated) were obtained with |log2FC|≥0.5 in group (A). The volcano plot is presented in Fig. 2A. A heat map by clustering analysis is presented in Fig. 3; it indicated that SP110 nuclear body protein and olfactory receptor 1645 separated the 2-week post-SCI group from the control group. The top five genes with maximum change are presented in Table II.
Figure 3.

Heat maps of the differentially expressed genes in 2-week post-SCI group vs. control group. SCI, spinal cord injury; Ctrl, control; post, post-SCI.

Table II.

Top five genes with maximum change in a 2-week time point, 1-month time point, 2-week and 1-month time point, and all samples respectively.

Probe set IDLog fold-changeP-valueSymbol
2-week
  10729312−0.944.21×10−4ENSRNOT00000011249
  10847189−0.929.93×10−3Olr697
  10910167−0.856.73×10−4ENSRNOT00000020374
  10812399−0.781.00×10−3Hapln1
  10846970−0.757.58×10−3LOC100365431
  10761128  1.412.53×10−4Hspb1
  10770710  1.834.50×10−5Atf3
  10750524  1.959.93×10−3Mx2
  10775624  2.062.84×10−5ENSRNOT00000063555
  10753425  2.435.09×10−3Mx1
1-month
  10709450−1.632.35×10−3Olr122
  10840577−1.191.60×10−3Cstl1
  10707992−1.172.23×10−3Klhl25
  10777123−0.931.97×10−3ENSRNOT00000037316
  10904593−0.918.74×10−3RGD1565410
  10938893  1.509.33×10−4Mir325
  10735369  1.553.82×10−3ENSRNOT00000052640
  10814301  1.574.79×10−3ENSRNOT00000053252
  10887088  1.864.58×10−3Mir544
  10775731  2.478.38×10−3Cxcl13
2-week and 1-month
  10733056−1.726.50×10−3Ifi47
  10775624−1.589.09×10−3ENSRNOT00000063555
  10840577−1.464.92×10−3Cstl1
  10909985−1.322.97×10−3ENSRNOT00000053078
  10936645−1.327.15×10−3RGD1563945
  10934666  1.417.43×10−3ENSRNOT00000057449
  10769215  1.523.12×10−3ENSRNOT00000059261
  10796258  1.708.65×10−3ENSRNOT00000052594
  10878815  1.835.88×10−4LOC690079
  10814301  2.254.23×10−3ENSRNOT00000053252
All samples
  10888931−0.893.55×10−4Abhd1
  10709450−0.725.53×10−3Olr122
  10878210−0.641.25×10−3Kank4
  10799241−0.621.87×10−3Idi1
  10708471−0.598.79×10−4Olr34
  10880731  1.524.31×10−6C1qc
  10936482  1.595.38×10−4Timp1
  10770710  1.621.34×10−7Atf3
  10761128  1.641.69×10−6Hspb1
  10775731  2.072.12×10−4Cxcl13
A total of 128 DEGs (24 downregulated and 104 upregulated) were obtained with |log2FC|≥0.5 in group (B). The volcano plot is presented in Fig. 2B. It was identified from the results of clustering analysis that cystatin-like 1 and ENSRNOT00000052640 separated the control group from the post-SCI group (Fig. 4). The top five genes with maximum change were presented in Table II.
Figure 4.

Heat maps of the differentially expressed genes in 1-month post-SCI group vs. control group. SCI, spinal cord injury; Ctrl, control; post, post-SCI.

A total of 133 DEGs (56 downregulated and 77 upregulated) were obtained with |log2FC|≥0.5 in group (C). The volcano plot was presented in Fig. 2C. A heat map by clustering analysis is presented in Fig. 5 and it indicated that cell death-inducing DFFA-like effector B and LOC689961 divided the samples into two groups. The top five genes with maximum change are presented in Table II.
Figure 5.

Heat maps of the differentially expressed genes in 1-month and 2-week post-SCI group vs. control group. SCI, spinal cord injury; Ctrl, control; post, post-SCI.

A total of 238 DEGs (11 downregulated and 227 upregulated) were obtained with |log2FC|≥0.5 in group (D). The volcano plot is presented in Fig. 2D. From the results of clustering analysis, it was identified that abhydrolase domain containing 1 and ENSRNOT00000053282 divided the samples into two groups (Fig. 6). The top five genes with maximum change are presented in Table II.
Figure 6.

Heat maps of the differentially expressed genes in all post-SCI groups vs. all control groups. SCI, spinal cord injury; Ctrl, control; post, post-SCI.

The Venn diagrams of the above four sets of DEGs [(A), (B), (C) and (D)] are presented in Fig. 7.
Figure 7.

Venn diagrams of four sets of differentially expressed genes. Post, post-spinal cord injury.

GO and pathway enrichment analyses

A total of 7 GO terms, 6 GO terms and 251 (9 KEGG and 242 GO) terms were obtained in DEGs of (A), (B) and (D), respectively following functional clustering analysis of the DEGs of the above four sets; there was no significant enrichment results in the DEGs of (C). The functional enrichment analysis of group (A) demonstrated that the DEGs were primarily enriched in GO terms associated with wound and inflammatory responses, including GO: 0009611-response to wounding and GO: 0002526-acute inflammatory response (Table III). The functional enrichment analysis of group (B) demonstrated that the DEGs were primarily enriched in GO terms associated with the immune system and inflammatory response, including GO: 0006955-immune response and GO: 0006954-inflammatory response (Table III). The enrichment analysis of DEGs identified in all samples of the (D) group demonstrated that the DEGs were primarily enriched in the GO terms and pathways associated with the immune system and inflammatory response, including GO: 0006955-immune response and GO: 0006954-inflammatory response, in addition to chemokine signaling pathway and high-affinity immunoglobulin E receptor (FcεRI) signaling pathway. Signal transducer and activator of transcription 3 (STAT3) and src family tyrosine kinase (LYN) are enriched in these two signaling pathways, respectively (Table III).
Table III.

GO and KEGG pathway enrichment analysis for differentially expressed genes.

TermDescriptionCountsP-value
2-week
  GO:0009611Response to wounding101.72×10−3
  GO:0002526Acute inflammatory response  52.82×10−3
  GO:0006954Inflammatory response  72.92×10−3
  GO:0006952Defense response  94.42×10−3
  GO:0001775Cell activation  75.00×10−3
  GO:0034097Response to cytokine stimulus  56.15×10−3
  GO:0051336Regulation of hydrolase activity  77.39×10−3
1-month
  GO:0006955Immune response112.16×10−6
  GO:0002684Positive regulation of immune system process  82.13×10−5
  GO:0050778Positive regulation of immune response  61.69×10−4
  GO:0002252Immune effector process  51.04×10−3
  GO:0048584Positive regulation of response to stimulus  61.63×10−3
  GO:0006954Inflammatory response  58.46×10−3
All samples
  GO:0006955Immune response401.84×10−25
  GO:0006952Defense response378.08×10−23
  GO:0001775Cell activation281.51×10−19
  GO:0009611Response to wounding346.34×10−19
  GO:0006954Inflammatory response252.35×10−17
  KEGG: rno04650:Natural killer cell mediated cytotoxicity133.22×10−8
  KEGG: rno05322:Systemic lupus erythematosus  96.82×10−5
  KEGG: rno04610:Complement and coagulation cascades  89.40×10−5
  KEGG: rno04662:B cell receptor signaling pathway  81.46×10−4
  KEGG: rno04060:Cytokine-cytokine receptor interaction122.11×10−4

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Following a BIND search, no known interaction among DEGs was identified in group (B). The network diagram of DEGs identified in group (A) is presented in Fig. 8A, and STAT3 and cbl proto-oncogene B, E3 ubiquitin protein ligase are in this diagram. Erb-B2 receptor tyrosine kinase 4 (ERBB4) was in the network diagram of DEGs identified in group (C; Fig. 8B). The network diagram of DEGs identified in group (D) is presented in Fig. 8C and cytochrome B-245, α polypeptide (CYBA), STAT3, protein tyrosine phosphatase, non-receptor type 6, S100 calcium binding protein A4 and Cluster of Differentiation 48 were in this diagram.
Figure 8.

Network diagram of (A) 2-week time points, (B) 2-week time and 1-month time series analysis and (C) the comparison between all control groups and all post-SCI groups.

Discussion

In the present study, with the dataset of GSE20907, 148, 128, 133 and 238 DEGs were obtained in the 2-week post-SCI group vs. control group, 1-month post-SCI group vs. control group, 1-month and 2-week post-SCI group vs. control group, and all samples, respectively. The results demonstrated that the DEGs were mainly associated with the immune system and inflammatory response. STAT3, ERBB4, and CYBA were in the network diagram of 2-week post-SCI group vs. control group, 1-month and 2-week post-SCI group vs. control group, and all samples, respectively. The enrichment analysis of DEGs identified in all samples demonstrated that the DEGs were also enriched in the chemokine and FcεRI signaling pathways, and that STAT3 and LYN are enriched in these two signaling pathways, respectively. SCI may initiate immune responses by producing cytokines and chemokines, and by infiltration of peripheral leucocytes, and thus SCI-induced inflammation may cause a further deterioration in certain functions (27). Furthermore, it is indicated that inflammation serves a part in neuroprotection, axonal regeneration and functional recovery following SCI (28). Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a pivotal regulator of inflammation and the suppression of astroglical NF-κB is able to reduce inflammation following SCI (29). Certain other studies also identify the important parts of the immune system and inflammatory response following SCI (30–32). In the present study, the DEGs were primarily associated with immune system and inflammatory response. The results therefore were in accord with previous studies and suggested that the immune system and inflammatory response served significant roles in the development of SCI. In the present study, ERBB4 and CYBA were in the network diagram of 1-month and 2-week post-SCI group vs. control group, and all samples, respectively. Lindholm et al (33) demonstrated that in the vicinity of the lesion, a number of scattered cells expressed ErbB mRNA following SCI. Neuregulin1/ErbB signaling may be involved in the development of SCI (34). Nakano et al (35) indicated that vestibular and immune defects may be caused by the mutation of the CYBA gene encoding p22phox. As stated above, the immune system serves an important role in the progression of SCI and thus, CYBA is associated with the progression of SCI via the immune system. Thus, the results of the present study were consistent with previous studies, and suggested that ERBB4 and CYBA may be key genes associated with SCI at a certain stage of the condition. In the present study, the enrichment analysis of DEGs identified in all samples demonstrated that the DEGs were also enriched in the chemokine signaling pathway and that STAT3 is enriched in this signaling pathway. STAT3 was in the network diagram of the 2-week post-SCI group vs. the control group. Chemokines may attract stem cells to the injured site and promote their survival following SCI (36). Taylor et al (37) suggested that cerebrospinal fluid cytokines and chemokines are dysregulated following acute thoracolumbar SCI in dogs. Chemokine-ligands/receptors are key mediator of secondary injury response following SCI (38) and STAT3, a transcription factor, is activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 (39). STAT3 is able to inhibit the spread of inflammation following SCI by regulating certain aspects of reactive astrogliosis, particularly the upregulation of glial scar formation and astrocyte hypertrophy, and the scar-forming astrocytes (40). Therefore, STAT3 may be a key gene associated with SCI and may be involved in the development of SCI via a chemokine signaling pathway. LYN, a non-receptor src-like tyrosine kinase, is a significant signaling mediator and is able to regulate apoptosis, differentiation and migration (41). Certain studies have suggested that LYN is involved in the process of oligodendrocyte differentiation (42,43) and serves a vital role in myelination in the brain (44). The number of newly-formed oligodendrocytes and the branches of the myelin membrane are decreased in FYN proto-oncogene Src family tyrosine kinase-deficient mice (45). Certain studies have suggested that the death of oligodendrocytes may cause spinal cord dysfunction and that minocycline treatment may reduce delayed oligodendrocyte death following SCI (46,47). In the present study, the enrichment analysis of DEGs identified in all samples demonstrated that the DEGs were also enriched in the FcεRI signaling pathway and that LYN is enriched in this pathway. Although the roles of the FcεRI signaling pathway have not been fully elucidated in SCI, it is hypothesized that LYN may be involved in the development of SCI via the FcεRI signaling pathway. In conclusion, the immune system and inflammatory response may serve significant roles in the development of SCI. STAT3, ERBB4 and CYBA may be key genes associated with SCI at a certain stage of the disorder. Furthermore, STAT3 and LYN may be involved in the development of SCI, via the chemokine and FcεRI signaling pathways, respectively. However, as the sample size of the present study was small and no experimental verification was performed, further studies on the mechanisms of SCI development are required.
  42 in total

1.  BIND: the Biomolecular Interaction Network Database.

Authors:  Gary D Bader; Doron Betel; Christopher W V Hogue
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

Review 2.  Epidemiology, demographics, and pathophysiology of acute spinal cord injury.

Authors:  L H Sekhon; M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

3.  Gene expression signature analysis and protein-protein interaction network construction of spinal cord injury.

Authors:  J Lai; X He; F Wang; J-M Tan; J-X Wang; S-M Xing; L-B Shen; L-Q Fang; P Yang; J-M Tan
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-11       Impact factor: 3.507

Review 4.  Review of current evidence for apoptosis after spinal cord injury.

Authors:  M S Beattie; A A Farooqui; J C Bresnahan
Journal:  J Neurotrauma       Date:  2000-10       Impact factor: 5.269

Review 5.  Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?

Authors:  M Wyndaele; J-J Wyndaele
Journal:  Spinal Cord       Date:  2006-01-03       Impact factor: 2.772

6.  Intrinsic response of thoracic propriospinal neurons to axotomy.

Authors:  Justin R Siebert; Frank A Middelton; Dennis J Stelzner
Journal:  BMC Neurosci       Date:  2010-06-04       Impact factor: 3.288

7.  Functions of the Lyn tyrosine kinase in health and disease.

Authors:  Evan Ingley
Journal:  Cell Commun Signal       Date:  2012-07-17       Impact factor: 5.712

8.  EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice.

Authors:  Yona Goldshmit; Mark D Spanevello; Sophie Tajouri; Li Li; Fiona Rogers; Martin Pearse; Mary Galea; Perry F Bartlett; Andrew W Boyd; Ann M Turnley
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

9.  PathwayVoyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.

Authors:  Eric Altermann; Todd R Klaenhammer
Journal:  BMC Genomics       Date:  2005-05-03       Impact factor: 3.969

10.  Further insight into molecular mechanism underlying thoracic spinal cord injury using bioinformatics methods.

Authors:  Weiguo Wang; Rongjun Liu; Zhanwang Xu; Xiufeng Niu; Zhaohu Mao; Qingxi Meng; Xuecheng Cao
Journal:  Mol Med Rep       Date:  2015-10-14       Impact factor: 2.952

View more
  1 in total

1.  The Network of miRNA-mRNA Interactions in Circulating T Cells of Patients Following Major Trauma - A Pilot Study.

Authors:  Cheng-Shyuan Rau; Pao-Jen Kuo; Hui-Ping Lin; Chia-Jung Wu; Yi-Chan Wu; Peng-Chen Chien; Ting-Min Hsieh; Hang-Tsung Liu; Chun-Ying Huang; Ching-Hua Hsieh
Journal:  J Inflamm Res       Date:  2022-09-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.